Michelle L Katz1, Zijing Guo2, Lori M Laffel3. 1. Pediatric, Adolescent and Young Adult Section, Boston, MA; Section on Clinical, Behavioral and Outcomes Research, Joslin Diabetes Center, Boston, MA. Electronic address: michelle.katz@joslin.harvard.edu. 2. Section on Clinical, Behavioral and Outcomes Research, Joslin Diabetes Center, Boston, MA. 3. Pediatric, Adolescent and Young Adult Section, Boston, MA; Section on Clinical, Behavioral and Outcomes Research, Joslin Diabetes Center, Boston, MA.
Abstract
OBJECTIVE: To evaluate hypertension and hyperlipidemia management patterns in youth with type 1 diabetes and to assess perceived effectiveness of management strategies and barriers to management. STUDY DESIGN: An electronic survey, including clinical scenarios, fielded to pediatric providers (members of the American Diabetes Association Diabetes in Youth Interest Group, Pediatric Endocrine Society, or T1D Exchange). RESULTS: Respondents (N = 207, 86% MDs, 68% female) were practicing clinicians for youth with type 1 diabetes. As an initial recommendation, the overwhelming majority of respondents (83%-99%) endorsed lifestyle and nonmedical recommendations (eg, improve glycemic control) for hypertension and hyperlipidemia. Yet, few (6%-17%) reported these recommendations as effective. Many respondents (57%) reported referring to another specialist for hypertension, whereas few (8%) reported referring to another specialist for hyperlipidemia management. Approximately one-fifth (21%) of respondents never initiate antihypertensive medications, whereas only 8% never initiate lipid-lowering medication. Among prescribers, the majority of respondents only started antihypertensive or lipid-lowering medications after persistent elevations and in the setting of either ineffective lifestyle or nonmedical interventions or additional cardiovascular risk factors. More than two-thirds of respondents endorsed medications as often effective for hypertension and hyperlipidemia (68% and 69%, respectively). CONCLUSIONS: Pediatric diabetes providers commonly defer prescribing antihypertensive and lipid-lowering medications until nonmedication interventions have been ineffective. Most providers describe medications, but not lifestyle interventions, as often effective. Efforts to align clinical practice with clinical guidelines are needed.
OBJECTIVE: To evaluate hypertension and hyperlipidemia management patterns in youth with type 1 diabetes and to assess perceived effectiveness of management strategies and barriers to management. STUDY DESIGN: An electronic survey, including clinical scenarios, fielded to pediatric providers (members of the American Diabetes Association Diabetes in Youth Interest Group, Pediatric Endocrine Society, or T1D Exchange). RESULTS: Respondents (N = 207, 86% MDs, 68% female) were practicing clinicians for youth with type 1 diabetes. As an initial recommendation, the overwhelming majority of respondents (83%-99%) endorsed lifestyle and nonmedical recommendations (eg, improve glycemic control) for hypertension and hyperlipidemia. Yet, few (6%-17%) reported these recommendations as effective. Many respondents (57%) reported referring to another specialist for hypertension, whereas few (8%) reported referring to another specialist for hyperlipidemia management. Approximately one-fifth (21%) of respondents never initiate antihypertensive medications, whereas only 8% never initiate lipid-lowering medication. Among prescribers, the majority of respondents only started antihypertensive or lipid-lowering medications after persistent elevations and in the setting of either ineffective lifestyle or nonmedical interventions or additional cardiovascular risk factors. More than two-thirds of respondents endorsed medications as often effective for hypertension and hyperlipidemia (68% and 69%, respectively). CONCLUSIONS: Pediatric diabetes providers commonly defer prescribing antihypertensive and lipid-lowering medications until nonmedication interventions have been ineffective. Most providers describe medications, but not lifestyle interventions, as often effective. Efforts to align clinical practice with clinical guidelines are needed.
Authors: Joseph T Flynn; David C Kaelber; Carissa M Baker-Smith; Douglas Blowey; Aaron E Carroll; Stephen R Daniels; Sarah D de Ferranti; Janis M Dionne; Bonita Falkner; Susan K Flinn; Samuel S Gidding; Celeste Goodwin; Michael G Leu; Makia E Powers; Corinna Rea; Joshua Samuels; Madeline Simasek; Vidhu V Thaker; Elaine M Urbina Journal: Pediatrics Date: 2017-08-21 Impact factor: 7.124
Authors: Rae-Ellen W Kavey; Vivek Allada; Stephen R Daniels; Laura L Hayman; Brian W McCrindle; Jane W Newburger; Rulan S Parekh; Julia Steinberger Journal: Circulation Date: 2006-11-27 Impact factor: 29.690
Authors: Olli T Raitakari; Markus Juonala; Mika Kähönen; Leena Taittonen; Tomi Laitinen; Noora Mäki-Torkko; Mikko J Järvisalo; Matti Uhari; Eero Jokinen; Tapani Rönnemaa; Hans K Akerblom; Jorma S A Viikari Journal: JAMA Date: 2003-11-05 Impact factor: 56.272
Authors: Kam Wong; Amy Potter; Shelagh Mulvaney; William E Russell; David G Schlundt; Russell L Rothman Journal: Diabetes Care Date: 2009-12-10 Impact factor: 19.112
Authors: Mark Daniels; Stephanie N DuBose; David M Maahs; Roy W Beck; Larry A Fox; Rose Gubitosi-Klug; Lori M Laffel; Kellee M Miller; Heather Speer; William V Tamborlane; Michael J Tansey Journal: Diabetes Care Date: 2013-04-22 Impact factor: 19.112
Authors: Evgenia Gourgari; Jeanette M Stafford; Ralph D'Agostino; Lawrence M Dolan; Jean M Lawrence; Santica Marcovina; Lina Merjaneh; Amy K Mottl; Amy S Shah; Dana Dabelea Journal: Pediatr Diabetes Date: 2020-05-05 Impact factor: 3.409